Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Post by FactFinder1994on May 17, 2021 10:20am
143 Views
Post# 33213575

Friend, Family, or COVER/Distraction

Friend, Family, or COVER/Distraction

 

This is not your typical public company.  
If you are here, your reason for being here likely falls in one of the categories above.
Remember, the Ownership of this company is unique.  
There has been next to NO EFFORT to share the SQI story (still).  
If you are fortunate enough to be aware of this story, you are among a very select group. 
At some point soon the powers at be will share the SQI story, and that will eliminate the unnecessary cover some like to provide here.  
Undervalued and Under Shared, and highly controlled....
Four shots on goal with FDA, all within weeks....and yet no one talks about it....  
 
A little more background on how tight the Ownership story is for SQI Diagnostics (SQD)....
 
Total Float ~ 340M Shares, w market cap of $85M CAD ($70M USD)
Approximate breakdown below....
 
Clive Beddoe (Chairman) ~ 86M = 26%
Gerold Connor (Director) ~ 86M = 26%
Wilmot Matthews (Director) ~ 87M = 26% 
Peter Lea (A Founder & Scientist) ~ 2M = 1% 
Other Insiders ~ 6M = 2%
 
Insiders represent approx 80% of the float.  
 
Next seven groups own approx 10% of the float.
 
Top dozen groups represent 90% of the float or approximately 305M shares.  
 
Remaining Float ~ 35M, or 10% of total shares.   
 
There is a very small percentage of the shares trading, among a very small group of handlers, determining SQI's value.  
The only reason handlers are able to prevail, is because the SQI story has not been shared.  
Given the reputations of those involved here I am sure they will not allow manipulation by a few to continue.
Value and Integrity comes with transparency, and an audience.  
People are dying in great numbers and hospital systems are overburdened, yet near silence here remains.      

<< Previous
Bullboard Posts
Next >>